New Multiple Myeloma Drug Drives Europe's Biggest Biotech Round

CellCentric has closed a $220 million oversubscribed Series D financing round to advance inobrodib — its first-in-class oral p300/CBP inhibitor — through pivotal trials in multiple myeloma. The round, led by Venrock Healthcare Capital Partners, is the largest private biotech financing in Europe so far in 2026 and reflects sustained institutional confidence in a drug that is targeting one of haematology's most persistently challenging diseases.

Multiple myeloma is a cancer of plasma cells in the bone marrow that remains incurable for most patients despite significant advances in treatment over the past decade. While therapies including proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy have extended survival meaningfully, relapse is almost universal — and patients who progress through multiple lines of therapy face rapidly narrowing options. Inobrodib targets the p300/CBP proteins that myeloma cells depend on to maintain their growth programme at the epigenetic level, offering a mechanism of action that is distinct from every currently approved therapy in the disease.

The $220 million Series D will advance inobrodib through Phase 2/3 trials toward registration — the stage at which the drug's clinical benefit will need to be demonstrated at the scale and rigour that regulators require for approval. The oversubscribed nature of the round signals that investors who have reviewed the existing clinical data are sufficiently confident in the programme to commit capital at this stage. For myeloma patients who have exhausted existing options, inobrodib represents one of the most scientifically differentiated candidates currently in late-stage development.